These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
822 related articles for article (PubMed ID: 27486755)
1. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. Mishra AK; Abrahamsson A; Dabrosin C Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755 [TBL] [Abstract][Full Text] [Related]
2. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599 [TBL] [Abstract][Full Text] [Related]
3. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412 [TBL] [Abstract][Full Text] [Related]
4. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477 [TBL] [Abstract][Full Text] [Related]
7. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234 [TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749 [TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
10. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells. Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780). Fitts JM; Klein RM; Powers CA J Pharmacol Exp Ther; 2011 Jul; 338(1):246-54. PubMed ID: 21464335 [TBL] [Abstract][Full Text] [Related]
12. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
13. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Martin LA; Pancholi S; Chan CM; Farmer I; Kimberley C; Dowsett M; Johnston SR Endocr Relat Cancer; 2005 Dec; 12(4):1017-36. PubMed ID: 16322340 [TBL] [Abstract][Full Text] [Related]
14. Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression. Tang H; Liao Y; Zhang C; Chen G; Xu L; Liu Z; Fu S; Yu L; Zhou S Oncol Res; 2014; 22(1):13-20. PubMed ID: 25700354 [TBL] [Abstract][Full Text] [Related]
15. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant. Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β. Galea GL; Meakin LB; Sugiyama T; Zebda N; Sunters A; Taipaleenmaki H; Stein GS; van Wijnen AJ; Lanyon LE; Price JS J Biol Chem; 2013 Mar; 288(13):9035-48. PubMed ID: 23362266 [TBL] [Abstract][Full Text] [Related]
17. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344 [TBL] [Abstract][Full Text] [Related]
20. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]